⚠ Disclaimer: This report is generated using AI tools and is for informational purposes only. It does not constitute investment advice. Please consult a registered financial advisor before making any investment decisions.
CAPLIPOINT - Fundamental Analysis: Financial Health & Valuation
Back to ListFundamental Rating: 4.4
| Stock Code | CAPLIPOINT | Market Cap | 12,479 Cr. | Current Price | 1,641 ₹ | High / Low | 2,397 ₹ |
| Stock P/E | 34.4 | Book Value | 243 ₹ | Dividend Yield | 0.36 % | ROCE | 28.6 % |
| ROE | 22.0 % | Face Value | 2.00 ₹ | DMA 50 | 1,746 ₹ | DMA 200 | 1,895 ₹ |
| Chg in FII Hold | 0.07 % | Chg in DII Hold | -0.05 % | PAT Qtr | 87.3 Cr. | PAT Prev Qtr | 103 Cr. |
| RSI | 37.9 | MACD | -30.4 | Volume | 85,132 | Avg Vol 1Wk | 70,839 |
| Low price | 1,551 ₹ | High price | 2,397 ₹ | PEG Ratio | 1.57 | Debt to equity | 0.00 |
| 52w Index | 10.6 % | Qtr Profit Var | 16.8 % | EPS | 47.7 ₹ | Industry PE | 27.6 |
📊 Financial Overview
- Revenue & Profitability: Quarterly PAT declined from 103 Cr. to 87.3 Cr., showing short-term weakness. EPS at 47.7 ₹ remains strong, supported by consistent profitability.
- Margins & Returns: ROE at 22.0% and ROCE at 28.6% are excellent, reflecting strong efficiency and shareholder returns.
- Debt Profile: Debt-to-equity ratio of 0.00 indicates a debt-free balance sheet, a major strength.
- Cash Flow: Strong operating margins and debt-free status ensure healthy cash flows.
💹 Valuation Indicators
- P/E Ratio: 34.4 vs Industry PE of 27.6 → slightly overvalued relative to peers.
- P/B Ratio: Current Price 1,641 ₹ vs Book Value 243 ₹ → P/B ~6.75, expensive compared to industry norms.
- PEG Ratio: 1.57 → indicates valuation premium relative to growth.
- Intrinsic Value: Trading above intrinsic value, suggesting limited near-term upside.
🏢 Business Model & Competitive Advantage
- Caplin Point Laboratories focuses on niche pharmaceutical markets, especially Latin America and emerging economies.
- Debt-free structure and strong ROCE provide resilience and competitive strength.
- Competitive advantage lies in cost-efficient manufacturing and focus on underserved markets.
📈 Technical & Entry Zone
- Stock trading at 1,641 ₹, below 50 DMA (1,746 ₹) and 200 DMA (1,895 ₹).
- RSI at 37.9 indicates oversold territory; MACD negative suggests short-term weakness.
- Entry Zone: Attractive between 1,550–1,600 ₹ for accumulation, with long-term holding potential.
✅ Positive
- Debt-free balance sheet.
- High ROE (22%) and ROCE (28.6%).
- Strong niche presence in emerging markets.
⚠️ Limitation
- High P/E and P/B ratios indicate premium valuation.
- Quarterly PAT decline from 103 Cr. to 87.3 Cr. shows short-term weakness.
📉 Company Negative News
- No major recent negative news, but profit decline in the latest quarter raises concerns.
📈 Company Positive News
- Debt-free status enhances financial stability.
- Institutional confidence reflected in slight increase in FII holdings (+0.07%).
🏭 Industry
- Pharmaceutical sector benefits from global demand and healthcare expansion.
- Industry PE at 27.6 indicates moderate valuations.
- Competition from larger pharma players remains a challenge.
🔮 Conclusion
- CAPLIPOINT shows strong fundamentals with excellent ROE/ROCE and debt-free balance sheet.
- Valuation appears stretched, but long-term prospects remain solid given niche focus and efficiency.
- Recommendation: Accumulate in the 1,550–1,600 ₹ range for long-term holding, targeting growth aligned with global pharma demand.